Physician profile
Gregory Cook
NPI 1992719454
$4,388.94
in general payments reported to CMS, 2019-2025
33 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $308 · 2021: $522 · 2022: $906 · 2023: $479 · 2024: $586 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.97 |
| Education | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,425.60 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $719.64 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $291.49 | 2019-2024 | |
| Duchesnay USA Incorporated | $214.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.60 | 2019-2023 | |
| Pfizer INC. | $159.30 | 2019-2024 | |
| Therapeuticsmd, INC. | $158.47 | 2019-2022 | |
| Exeltis, USA INC. | $127.39 | 2021-2025 | Slynd |
| Organon LLC | $122.79 | 2021-2024 | Nexplanon |
| Mayne Pharma Commercial LLC | $95.45 | 2022-2025 | |
| Biogen, INC. | $83.15 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $79.92 | 2023 | Ova1 |
| Medtronic, INC. | $77.34 | 2022-2024 | Plasmablade(Tm) |
| Nalpropion Pharmaceuticals LLC | $70.91 | 2019 | |
| Hologic Sales and Service, LLC | $52.67 | 2021-2023 | Aptima, Novasure |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $52.23 | 2019-2020 | |
| Amgen INC. | $47.88 | 2019 | |
| Roche Diagnostics Corporation | $47.10 | 2019 | |
| Sumitomo Pharma America, INC. | $46.85 | 2023 | Myfembree |
| Amag Pharmaceuticals, INC. | $40.31 | 2019 | |
| Shield Therapeutics INC | $36.93 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $35.76 | 2019-2022 | |
| Millicent US INC | $35.19 | 2024 | Femring, Intrarosa |
| Alydia Health | $29.33 | 2021 | |
| Coopersurgical, INC. | $21.95 | 2021 | |
| Convatec INC. | $21.81 | 2023 | |
| Lilly USA, LLC | $19.15 | 2024 | Zepbound |
| Pacira Pharmaceuticals Incorporated | $18.77 | 2022 | |
| Kvk-Tech, INC. | $14.47 | 2019 | |
| Lupin INC. | $13.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.86 | 2020 | |
| Becton, Dickinson and Company | $11.65 | 2022 | |
| Channel Medsystems, INC. | $5.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.